Hundreds of lawsuits have been filed against GLP-1 drug makers Eli Lilly and Novo Nordisk alleging their weight-loss medications, including Ozempic and Mounjaro, caused permanent vision loss through a condition called NAION. The plaintiffs claim the drugmakers failed to warn patients of this side effect, though it appears on labels in some other countries. Both companies deny a significant link between their drugs and vision loss.
Hundreds of consumers are suing manufacturers of GLP-1 weight-loss drugs, claiming they cause NAION, a rare eye condition leading to sudden vision loss. Research shows mixed results with some studies finding increased NAION risk in semaglutide users, though observational evidence cannot prove causation, and regulatory agencies remain under investigation without issuing formal warnings.